The effect of DASH diet on NAFLD

The effect of DASH-based weight loss diet on serum Lipopolysaccharide level and meta-inflammation status among patients with non-alcoholic fatty liver disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20100209003320N17

Enrollment

Registered

2019-12-22

Start date

2019-10-23

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: Patients in this group will receive the DASH-based weight loss diet for 8 weeks. Intervention 2: Control group: Patients in this group will receive the usual weight

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Ages 20-50 Grade 1 and 2 NAFLD disease Body mass index in the range of 30-40 Kg / m2 Willingness to cooperate

Exclusion criteria

Exclusion criteria: Alcohol consumption Pregnancy Breastfeeding Menopause Being an athlete Having a weight loss diet 3 months before the study The use of lowering blood sugar , lipid , blood pressure drugs , antibiotics and corticosteroids Suffering from metabolic disease , cardiovascular , renal , kidney stone , liver disease , thyroid disease , autoimmune and cancer

Design outcomes

Primary

Measure	Time frame
Calorie and macronutrients intake. Timepoint: Baseline and 4 weeks after the intervention and 8 weeks after the intervention. Method of measurement: The intake of calorie and macronutrients from the diet of the subjects with using a 3 day food record questionnaire and analysis by the nutritionist 4 program.;Anthropometric Indices. Timepoint: Baseline and 8 weeks after the intervention. Method of measurement: Measurement of height and weight without shoes and with minimum clothes on, by Seca stadiometer and scale, respectively. Measurement of waist and hip circumference by a tape measure and body mass index (BMI) by dividing weight (kg) by height squared (m2).;Liver enzymes (ALT , AST ). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Enzymatic method.;Serum levels of lipopolysaccharide. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: ELISA.;Inflammatory indices ( MCP-1 , TLR-4 ). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: ELISA.	—

Measure

Time frame

Calorie and macronutrients intake. Timepoint: Baseline and 4 weeks after the intervention and 8 weeks after the intervention. Method of measurement: The intake of calorie and macronutrients from the diet of the subjects with using a 3 day food record questionnaire and analysis by the nutritionist 4 program.;Anthropometric Indices. Timepoint: Baseline and 8 weeks after the intervention. Method of measurement: Measurement of height and weight without shoes and with minimum clothes on, by Seca stadiometer and scale, respectively. Measurement of waist and hip circumference by a tape measure and body mass index (BMI) by dividing weight (kg) by height squared (m2).;Liver enzymes (ALT , AST ). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: Enzymatic method.;Serum levels of lipopolysaccharide. Timepoint: Baseline and 8 weeks after intervention. Method of measurement: ELISA.;Inflammatory indices ( MCP-1 , TLR-4 ). Timepoint: Baseline and 8 weeks after intervention. Method of measurement: ELISA.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarnaz Rouhollahzadegan

Tabriz University of Medical Sciences

farnazrz69@gmail.com+98 41 3335 7582

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026